Toleranzia attends international scientific conference on myasthenia gravis in the USA
10 maj - 2022
Toleranzia AB (publ) ("Toleranzia" or the "Company") today announces that it will participate in The 14th MGFA International Conference on Myasthenia And Related Disorders, which is organized every five years by the Myasthenia Gravis Foundation of America (MGFA). Preclinical data for Toleranzia's most advanced drug candidate, TOL2, will be presented at the conference. The conference brings together the world's leading players in myasthenia gravis and will take place from 10-12 May 2022 in Miami, USA.
Myasthenia gravis is an autoimmune disease caused by the immune system mistakenly attacking the receptors that control the body's muscles. The disease, which is progressive, can lead to a significant deterioration in the patient's mobility and can ultimately cause a life-threatening deterioration of the respiratory muscles. Today, only symptomatic treatments are available for the disease and there is a great medical need for new and better therapies and a better understanding of the basic mechanisms of the disease. Every five years, the world's leading scientists, physicians and drug developers gather to discuss the state of the art.
Toleranzia's drug candidate TOL2 is being developed with the aim of becoming the first disease-modifying treatment for myasthenia gravis and the company's Chief Medical Officer, Vidar Wendel-Hansen, will attend the meeting in Miami to disseminate knowledge about TOL2 to other researchers, physicians and potential collaborators. Toleranzia's CEO Charlotte Fribert and the Company's Chief Business Officer Björn Löwenadler will attend the meeting virtually.
Toleranzia's scientific progress on TOL2 will be presented by research collaboration partner Konstantinos Lazaridis from the Hellenic Pasteur Institute in Athens. Dr. Lazaridis will present important preclinical results that clearly demonstrate the potential for TOL2 to become a disease-modifying treatment for myasthenia gravis.
"The conference is a great opportunity for us to meet the world's leading scientists, doctors and representatives from the pharmaceutical industry who are all working to help patients affected by myasthenia gravis. Toleranzia has a unique concept to offer, and we are also in a very exciting position as we are currently preparing the upcoming clinical trial of the drug candidate TOL2", says Charlotte Fribert, CEO of Toleranzia.
For further information, please contact:
Charlotte Fribert – CEO, Toleranzia
Tel: +46 763 19 98 98
About Toleranzia AB (publ)
Toleranzia AB (publ) develops drugs that harness the power of the immune system for the treatment of autoimmune orphan diseases. The drugs, which target the cause of the disease, can cure or significantly alleviate the disease and not, like current treatments, merely reduce the symptoms. They have the potential to be the first long-acting or curative therapies that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. Toleranzia's shares are listed on the Nasdaq First North Growth Market and Mangold Fondkommission AB, 08-503 015 50, CA@mangold.se, is the Company's Certified Adviser.